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ABSTRACT 
Background and aims 
Hepatitis C (HCV) is a leading cause of morbidity and mortality in people who live with HIV. In 
many countries, access to direct acting antiviral agents to treat HCV is restricted to individuals with 
advanced liver disease (METAVIR stage F3 or F4). Our goal was to estimate the long term impact of 
deferring HCV treatment for men who have sex with men (MSM) who are coinfected with HIV and 
often have multiple risk factors for liver disease progression.  
Methods  
We developed an individual-based model of liver disease progression in HIV/HCV coinfected men 
who have sex with men. We estimated liver-related morbidity and mortality as well as the median 
time spent with replicating HCV infection when individuals were treated in liver fibrosis stages F0, 
F1, F2, F3 or F4 on the METAVIR scale.  
Results 
The percentage of individuals who died of liver-related complications was 2% if treatment was 
initiated in F0 or F1. It increased to 3% if treatment was deferred until F2, 7% if it was deferred until 
F3 and 22% if deferred until F4. The median time individuals spent with replicating HCV increased 
from 5 years if treatment was initiated in F2 to almost 15 years if it was deferred until F4.  
Conclusions  
Deferring HCV therapy until advanced liver fibrosis is established could increase liver-related 
morbidity and mortality in HIV/HCV coinfected individuals, and substantially prolong the time 
individuals spend with replicating HCV infection.  
  
INTRODUCTION 
Liver disease has become a leading cause of mortality in people who live with HIV (PWLH); it is 
often caused by infection with the Hepatitis C virus (HCV) [1, 2]. In high-income countries, about 
30% of HIV-positive individuals are coinfected with HCV, though the proportion varies by risk 
group. As many as 70-90% of HIV-positive intravenous drug users are coinfected with HCV [3]. In 
the population of HIV-positive men who have sex with men (MSM) [4-6], HCV incidence has 
increased in recent years. The accelerated fibrosis progression observed in some studies [7-9], and the 
high incidence of HCV seroconversions and reinfections underscore the need for reliable predictions 
of the HCV disease burden and of the optimal therapeutic interventions in this population. Successful 
HCV treatment greatly reduces the risk of decompensated cirrhosis, hepatocellular carcinoma (HCC) 
and extrahepatic complications, but does not eliminate it [10-15]. Because HIV coinfected individuals 
have multiple risk factors for liver disease, including drug toxicity and metabolic liver disease, they 
might be at increased risk to have liver-related complications even after they clear HCV [12, 14, 16]. 
We do not know if treatment can be deferred until METAVIR stages ≥ F3 without increasing the risk 
of liver-related complications [17].  
For the last decade, the standard of care for people infected with HCV has been treatment with 
pegylated-interferon-α (PEG-IFN) plus ribavirin (RBV). This IFN-based regimen is challenging to 
use, especially in HIV coinfected individuals who are at high risk for serious side-effects and have a 
low probability of cure [18-20]. Recently, new direct acting antivirals (DAAs) have revolutionized the 
treatment of HCV. These compounds are very effective, easy to use, and have few contraindications. 
These are factors that greatly increase the proportion of PWLH eligible for HCV treatment [21-24]. 
Yet the very high cost of the DAAs represents a major barrier to widespread treatment scale up and is 
a matter of debate [25]. Although the European Association for the Study of the Liver (EASL) now 
recommends that individuals coinfected with HIV are prioritized for treatment regardless of their 
fibrosis stage [26], reimbursement of HCV therapy is often restricted to individuals with advanced 
liver fibrosis [17, 27-29] .  
 
  
We set out to estimate the impact of deferring HCV treatment on of liver-related complications in 
HIV coinfected individuals by using a model of liver disease progression and care. Our main 
outcomes of interest were liver-related morbidity and mortality as well as the time spent with 
replicating HCV.   
 
METHODS  
Data sources 
We parameterized the model with data from the Swiss HIV Cohort Study (SHCS) and published 
literature. The SHCS (www.shcs.ch) is a prospective cohort study of PWLH in Switzerland that 
includes about 45% of all HIV-positive individuals declared to the public health authorities, and about 
70% of all individuals with AIDS [30]. Detailed demographic, clinical and laboratory characteristics, 
HCV genotypes, treatment rates, and estimated duration of HIV infection are collected at baseline and 
during follow-up visits every six months.  
Model structure and inputs 
We developed the model using ‘gems’, an R package that enables the creation of multistate models 
with generalized hazard functions [31, 32]. Figure 1 shows the structure of the model, which is 
organized in two dimensions: progress of liver disease and cascade of HCV care. We defined the 
stages of liver disease, from healthy liver to cirrhosis (F0-F4) based on the METAVIR scoring 
system. Individuals in METAVIR stage F4 could progress to decompensated cirrhosis or HCC. 
Progression from decompensated cirrhosis to HCC was also possible. At any disease stage, 
individuals were allowed to progress along the cascade of care: they could be diagnosed, treated, and 
succeed or fail treatment. Individuals could also spontaneously clear the infection. Death could occur 
in any state.  
We present the model’s input parameters in Table S1. Simulated individuals were assigned the 
following characteristics at time of HCV infection: age, HCV genotype, and METAVIR stage (see 
  
details in appendix). We derived the distribution of these characteristics from the SHCS dataset 
(Table 1). When we calculated the HCV diagnosis rate, we assumed that individuals were screened 
annually for HCV antibodies, with a sensitivity that increased from 25% at time of HCV infection to 
95% after one year [33], and that elevated liver enzymes would reveal 88% of  infections within the 
first three months of infection [33]. We assumed the progress of liver disease was the same across the 
METAVIR stages, and increased with older age at time of infection with HCV [34]. We assumed that 
clearing HCV decreased the rate at which fibrosis progressed from F0 to F4 (rate ratio RR=0.1), from 
F4 to decompensated cirrhosis (RR=0.1), and from F4 to HCC (RR= 0.38) [10] (see details in 
appendix). The probability of spontaneously clearing HCV followed a logistic decrease over a year, 
with an overall probability of 32%. Treatment rates and outcomes differed across scenarios.  
We modelled one baseline scenario (“SHCS scenario”) and 5 interventions (“DAA scenarios”). The 
SHCS scenario was designed to reproduce current practice in the SHCS before second-generation 
DAAs were introduced. Individuals were treated with PEG-IFN/RBV. Those with chronic HCV 
genotype 1 infection also received a first-generation DAA. We assumed that adding a first generation 
DAA (telaprevir, boceprevir or faldaprevir) to PEG-IFN/RBV increased the probability of treatment 
success (RR=2.17) [35]. The probability of treatment success followed a logistic decrease from 0.9 at 
the time of HCV infection to the genotype-dependent probabilities described for chronic HCV two 
years after infection (see details in appendix). Treatment response rates were lower in people who had 
compensated cirrhosis than in non-cirrhotic people (RR= 0.74) [36]. 
In our DAA scenarios, all diagnosed individuals were treated with second generation DAAs; the 
probability of treatment success differed by HCV genotypes and cirrhosis status (Table S1). We 
modelled five scenarios, in which individuals were treated when they reached METAVIR stages F0, 
F1, F2, F3 or F4.  
Model outcomes 
The clinical outcomes of the model were cirrhosis, decompensated cirrhosis, HCC, liver-related 
deaths, and time spent with replicating HCV.  
  
Sensitivity analysis 
The uncertainty around the key parameter, the fibrosis progression rate by age at HCV infection 
(Table S1) was taken into account in the main analysis by sampling these parameters from a 
multivariate normal distribution. To assess the robustness of our main results, we investigated the 
effect of modifying our assumptions on the following parameters: progress of liver-fibrosis between 
F0 and F4 before and after HCV clearance, and progression from F4 to the outcomes (see details in 
appendix).  
The impact of HCV reinfections was assessed by building an alternative model. In this model we 
assumed that either 9% of the individuals who had cleared an HCV infection were reinfected after a 
median time of 3.3 year as observed in the SHCS [37], or that 22% were reinfected after a median 
time of 2.1 years as described by Martin et al. [38]. In these scenarios, reinfected individuals were not 
retreated in order to obtain an estimate of the “worst-case-scenario”. 
Cost calculations 
We calculated the cost per 100 HCV infections in our five DAA scenarios by adding the cost of 
disease stages to the treatment costs. We estimated the mean patient cost by disease stage based on 
data collected at the University Hospital Zurich, Switzerland. The data included the whole population 
of HCV infected individuals (not only HIV-coinfected). We used the cost of a 12-week course 
regimen with sofosbuvir + ledipasvir in Switzerland.  
  
  
RESULTS  
The SHCS scenario 
This scenario is based on current HCV treatment strategies prior to the availability of second 
generation DAAs. We estimate that 46% of the simulated HIV/HCV-infected individuals developed 
liver cirrhosis over their lifetime, 11% experienced decompensated cirrhosis and 17% HCC (Figure 
2). Of the simulated individuals 27% died of liver-related causes, and 0.8% died of liver-related 
complications after they cleared HCV.  
The second generation DAAs scenarios  
The effect of deferring HCV treatment until later stages of liver fibrosis is shown in Figure 3a. The 
percentage of simulated individuals who died of liver-related complications was 2% if treatment was 
initiated in F0 or in F1. It rose to 3% if treatment was deferred until F2, 7% if deferred until F3, and 
22% if deferred until F4.  
Of individuals who died of liver-related complications, less than 1% died after clearing HCV if they 
were treated as they reached F0 or F1. This percentage increased to 2% if treatment was deferred until 
F2, 6% if it was deferred until F3, and 17% if it was deferred until F4 (Figure 3b). A large proportion 
of liver-related deaths occurred in individuals without replicating HCV if treatment was deferred until 
advanced fibrosis or cirrhosis as the model assumed that SVR substantially reduces the risk of liver 
disease progression but does not eliminate it  [10-15]. The median time spent with replicating HCV 
increased from 5 years if treatment was initiated in F2 to almost 15 years if treatment was deferred 
until F4 (Figure 4). The percentages of individuals who died from liver-related complications 
depending on the follow up time since HCV infection are shown in Supplementary Table S2. 
Sensitivity analysis 
Figure S1 shows the impact of varying the key input parameters on the percentage of individuals who 
die of liver-related complications. Our base analysis is the one described above (all 5 DAA scenarios). 
  
Results are described in the appendix. The claim that early treatment can prevent liver-related deaths 
was true in most analyses, unless we assumed an extremely high rate of fibrosis progression (Figure 
S1e), or that liver disease never progressed after HCV was cleared (Figure S1b).   
Figures S2 and S3 show the impact of HCV reinfections. Assuming that 9% of the individuals who 
cleared HCV infection were reinfected [37], the difference in the proportion of liver related deaths 
between the different scenarios was lower compared to the base scenarios. The percentage of 
individuals who died of liver-related complications was 7% if individuals were treated in METAVIR 
stage F0 or F1 and 8% if they were treated in F2. It increased to 12% if treatment was deferred until 
F3 and to 26% if it was deferred until F4. When we assumed that 22% experienced a reinfection as 
observed by Martin et al. [38], the percentage of individuals who died of liver-related complications 
was 15% if individuals were treated in F0, F1 or F2. It increased to 18% if treatment was deferred 
until F3 and to 30% if it was deferred until F4. 
Cost calculations 
The total cost, including disease and treatment costs, per 100 HCV infections only varied between 4.8 
and 5.9 million Euros, depending on the timing of HCV treatment (Table S3, see appendix for 
details). 
  
  
DISCUSSION 
Principal findings 
Over a lifetime, deferring HCV treatment until advanced liver disease stages is likely to substantially 
increase liver-related complications, increase the time individuals spend with replicating HCV, and 
may not save money. 
In many settings, cost considerations and related limitations in reimbursement by health insurances 
have led the authorities to recommend that HCV treatment be deferred until METAVIR stage F3 or 
more. Our model showed that initiating HCV therapy in METAVIR stage F2 instead of deferring 
treatment until stage F3 or F4 could prevent 4-19 liver-related deaths per 100 HCV infections. In the 
scenario where all diagnosed individuals are treated with DAAs in METAVIR stages F3 or F4, most 
liver-related deaths were caused by liver disease progression after HCV clearance, rather than because 
of treatment failure or a lack of diagnosis. Thus, if treatment is deferred until advanced fibrosis or 
cirrhosis has developed, most liver-related deaths will occur after HCV is cleared. HCV clearance is 
often associated with fibrosis regression, but liver fibrosis may progress in some individuals after 
HCV clearance [10, 12, 16, 17, 39-42]. Accordingly, deferring treatment until advanced fibrosis 
increased liver-related morbidity and mortality in all scenarios except when we assumed that liver 
fibrosis never progressed after SVR, or in a scenario with an extremely fast fibrosis progression. This 
is plausible since many risk factors associated with fibrogenesis, including drug toxicity, alcohol use, 
coinfections or metabolic liver disease, persist after cure. HCC can occur in those with cirrhotic livers 
even after they clear HCV [10]. Reinfections have been observed in up to 22% of patients following 
spontaneous or treatment-induced HCV clearance [38]. As expected, the benefit of treating 
individuals earlier was partially offset through reinfections and the proportion of patients who 
experienced liver related events was higher if reinfections were considered (see Figures S2 and S3). 
However, even in a worst-case-scenario assuming a very high reinfection rate and no retreatment, 
treating earlier reduced liver-related complications.  
  
We show that initiating HCV therapy in F2, instead of F3 or F4, reduced the time individuals spent 
with replicating HCV by 47-64% as compared to when therapy is started in F1. Initiating therapy in 
F1, instead of waiting until F3 or F4 reduced the median time spent with replicating HCV by 85-90%. 
Early treatment reduced the median time with replicating HCV even in our worst case scenario where 
reinfected individuals were not retreated. This may decrease the risk of further HCV transmission in 
those with high-risk behavior. This is particularly important for HIV-positive MSM since this 
population is in the midst of an increase in HCV transmissions. Earlier initiation of treatment could be 
a valuable preventive strategy, akin to the concept of treatment-as-prevention in HIV, which was 
established as a very effective measure to reduce HIV transmissions [43]. A recent study in the SHCS 
found that increased treatment uptake and efficacy can reduce the proportion of individuals with 
replicating HCV infection [37].  
Our cost calculations suggest that, despite the very high cost of treatment, early treatment might not 
increase total spending, since the increase in treatment cost is balanced by the savings in health care 
costs. This is assuming that prices of DAA therapy do not decrease in the coming years.  
Comparison with other studies  
Three other studies modelled the effect of timing of HCV therapy. The first investigated the effect of 
deferring HCV therapy in HCV-genotype 1 monoinfected individuals [44]. Researchers compared the 
cost-effectiveness of initiating therapy in different stages of liver disease and found it did not have 
much impact on the life expectancy. The second study examined the cost-effectiveness of early HCV 
treatment for individuals with HCV monoinfection and concluded that treating those with moderate or 
advanced fibrosis was cost-effective; the cost-effectiveness of treating those with minimal or no 
fibrosis depended on the cost of treatment [45]. The third study estimated the quality-adjusted life-
years for a 40 years old patient to increase from 23.9 if treatment was started in F4 to 33.7 if treatment 
started in F0 assuming and SVR rate of 90% [46]. These studies considered only cohorts of HCV 
monoinfected individuals. The first assumed that successful HCV treatment would eliminate further 
risk of liver disease progression, the second and the third assumed that only individuals treated in F4 
  
were still at risk of liver-disease progression after HCV clearance. In contrast, our model assumes that 
liver fibrosis progresses in some individuals [13, 14, 16, 40], which led to an increase in liver-related 
events if therapy was deferred until F3.  
Of note, a recent cost-effectiveness analysis among HIV/HCV coinfected patients suggested that IFN-
free regimens will be cost-effective if treatment costs were below 109’000 USD, which is now the 
case in many settings [47]. For the Swiss setting, a recent study suggested that DAA-based therapies 
were cost-effective even at current prices if a threshold of 100,000 CHF per QALY was assumed [48]. 
Another study published in 2015 demonstrated that cost-effectiveness is highly sensitive to drug 
prices and that treating patients in F0 would be cost-effective if treatment costs were below 50’000 
USD [49]. A recent study [50] showed that the life-expectancy of HCV-monoinfected individuals 
who had been successfully treated in an advanced liver-disease stage was comparable to that of the 
general population. The apparent inconsistency between this finding and our results can be explained 
by the differences between the cohorts, including different patient characteristics and very different 
follow-up times. The median follow-up time in that study was 8.4 years, while we make predictions 
over a life-time. In fact, when we simulated a cohort of individuals cured in an advanced stage of the 
disease, our model predicted a very low percentage (1.2%) of liver-related deaths after 8.4 years of 
follow-up (see appendix). A recent meta-analysis [10] estimated a 5-year risk of HCC after SVR of 
2.9% in the overall population, and 5.3% among cirrhotic individuals.  
Strengths and limitations 
Our study was strengthened by our access to observed data from a large and nationally representative 
cohort of PWLH. Data were collected prospectively during regular follow-up visits and include 
detailed demographic, clinical and laboratory data on HIV and HCV infections. The individual-based 
design of our model enabled us to exploit this detailed information. The use of the R package ‘gems’ 
allowed us to model time-dependant transition rates for spontaneous HCV clearance and treatment 
success. The very flexible structure of the model also allowed us to adapt parameters quickly as new 
data became available.  
  
Our study also has several limitations. First, we derived some input parameters from the literature, 
which implies heterogeneity in both data collection and reporting. Second, the results apply primarily 
to HIV-positive MSM and might not be generalizable to HIV-positive people who acquired HCV 
through injecting drug use with different demographic and clinical characteristics. Third, disease-costs 
for each fibrosis stage were calculated as total health-care costs excluding treatment as described 
before [51]. As these costs include potential costs due to interferon-related side effects, the disease 
stage costs could overestimate the true costs in the interferon-free DAA era. Fourth, cost calculations 
are highly dependent on the future developments in DAA prices and differ substantially between 
countries and recommended regimens. Therefore, cost estimates from this study might not be 
applicable to other settings. Fifth, the costs averted by preventing complications after secondary HCV 
infections was not considered, leading to an underestimation of the benefit of early treatment on costs. 
Sixth, we did not explicitly model that, after cure, liver fibrosis regresses in some individuals while it 
progresses in others [12, 39-41]. We instead used an average between individuals who continue to 
have liver fibrosis progression, those who remain stable, and those who regress their fibrosis, 
corresponding to a tenfold reduction in fibrosis progression after HCV clearance. Given published 
data on liver-disease progression in both HIV-monoinfected individuals, as well as in HIV/HCV 
coinfected individuals after SVR, this is a conservative estimate of the risk of liver-disease 
progression after HCV clearance. Seventh, we did not consider possible discrepancies between the 
measured and the real stage of liver-disease, though we are aware that non-invasive diagnostic tools 
are not ideal predictors of liver fibrosis [52]. People classified as F3 could already be cirrhotic, but 
this is only an additional argument against deferring HCV therapy. Eighth, in the SHCS scenario, we 
did not model explicitly the side effects of IFN-based treatment. However, to some extent this was 
accounted for by the lower cure rates in the SHCS if side effects were present. Ninth, the impact of 
resistant variants emerging after relapse on the effectiveness of DAA therapies could not be 
investigated with the present model. 
Implications of findings 
  
Deferring HCV therapy until advanced liver fibrosis is established may increase the percentage of 
liver-related complications in people who have multiple risk factors for liver disease progression, such 
as HIV-coinfected MSM. Our model predicts that the time individuals spend with replicating HCV 
can be greatly shortened by early treatment. This may decrease further HCV transmissions in those 
with high-risk behavior. Both findings support arguments that HCV therapy should be accessible to 
everyone at an early stage. To make this affordable for health insurances and governments, the costs 
for DAA drugs need to be lowered substantially. Our findings support current recommendations to 
start HCV treatment irrespective of fibrosis stage in those with risk factors for accelerated fibrosis 
progression including HIV-coinfected MSM, and in persons at elevated risk of HCV transmission 
[26]. 
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FIGURES LEGENDS: 
Figure 1: Model structure 
Individuals can progress vertically through the METAVIR fibrosis stages (F0 to F4) and the 
endpoints: DC (decompensated cirrhosis) and HCC (hepatocellular carcinoma). From any of those 
stages individuals can also progress horizontally along the care cascade and be diagnosed, put onto 
treatment, fail treatment or be cured. Individuals who clear HCV, either spontaneously or because 
they were succeeded treatment have undetectable HCV. The rates of progression through the 
METAVIR stages depends on several factors including whether the individual has undetectable HCV 
(upper right block) or not (all other blocks).  
Figure 2: The SHCS scenario 
a) Cumulative incidence of any METAVIR fibrosis stages (F0-F4), decompensated cirrhosis (DC) and 
hepatocellular carcinoma (HCC) over time.  
b) Percentage of individuals who experience F4, DC, HCC over their lifetime or die of liver related 
complications.  
Figure 3: The DAA scenarios 
a) Impact of deferring HCV treatment on liver-related complications. The figure shows the percentage 
of individuals who experience F4 (cirrhosis), DC (decompensated cirrhosis), HCC (hepatocellular 
carcinoma) and liver-related deaths for different treatment scenarios.  
b) Percentage of individuals who die of liver-related complications with or without replicating HCV 
infection. F0-F4: METAVIR fibrosis stages. 
 
Figure 4: Median years with replicating HCV infection, by treatment scenarios 
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i modelled with a Weibull function of the form 𝑓𝑓 =  𝜅𝜅
𝜆𝜆
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𝜆𝜆
𝜅𝜅−1
𝑒𝑒−
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𝜆𝜆
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 with κ=4.23 and λ=40.22 
ii not used in the model 
TABLE 1.  
CHARACTERISTIC AT HCV DIAGNOSIS  Value Reference 
Median age in years (IQR)   34 (21-47) i  SHCS data 
Duration of HIV infection in years (%) 
≤ 5  
6-10  
11-15 
16-20 
>20 
  
32.7  
26.2  
18.7  
16.8 
5.6  
SHCS data 
 
Median CD4 cells/μl (IQR) ii  459 (320-649) SHCS data 
With suppressed HIV RNA (%) ii  81  
HCV Genotype (%) 
1 
2 
3 
4 
  
66.7 
[1] 
 1.6 
 12.7 
 19.0 
METAVIR stage at HCV infection (%) 
F0 
F1 
F2 
F3 
F4 
  
85.9 
Simulated using duration 
of HIV infection and RR of 
liver fibrosis progression 
(see appendix for details) 
 15.1 
 1.8 
 0.2 
 0.02 
                                                          
  
 
